Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 29 articles:
HTML format
Text format



Single Articles


    June 2018
  1. NAVARRO HI, Goldstein AS
    HoxB13 mediates AR-V7 activity in prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Jun 11. pii: 1808196115.
    PubMed     Text format    


    May 2018
  2. CHEN Z, Wu D, Thomas-Ahner JM, Lu C, et al
    Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Proc Natl Acad Sci U S A. 2018 May 29. pii: 1718811115.
    PubMed     Text format     Abstract available


    April 2018
  3. FAN L, Zhang F, Xu S, Cui X, et al
    Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2018 Apr 30. pii: 1802415115.
    PubMed     Text format     Abstract available


  4. TAKAYAMA KI, Suzuki T, Fujimura T, Takahashi S, et al
    COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 23. pii: 1721957115.
    PubMed     Text format     Abstract available


  5. LEE JK, Bangayan NJ, Chai T, Smith BA, et al
    Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 23. pii: 1802354115.
    PubMed     Text format     Abstract available


  6. ELLIS L, Loda M
    LSD1: A single target to combat lineage plasticity in lethal prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 16. pii: 1804205115.
    PubMed     Text format    


  7. POWELL GRAY B, Kelly L, Ahrens DP, Barry AP, et al
    Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 16. pii: 1717705115.
    PubMed     Text format     Abstract available


    March 2018
  8. SEHRAWAT A, Gao L, Wang Y, Bankhead A 3rd, et al
    LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Proc Natl Acad Sci U S A. 2018 Mar 26. pii: 1719168115.
    PubMed     Text format     Abstract available


    October 2017
  9. KUNDU M, Roy A, Pahan K
    Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma.
    Proc Natl Acad Sci U S A. 2017;114:11482-11487.
    PubMed     Text format     Abstract available


    September 2017
  10. TAKAYAMA KI, Suzuki T, Fujimura T, Yamada Y, et al
    Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.
    Proc Natl Acad Sci U S A. 2017 Sep 11. pii: 201706076.
    PubMed     Text format     Abstract available


    June 2017
  11. FEI T, Chen Y, Xiao T, Li W, et al
    Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.
    Proc Natl Acad Sci U S A. 2017 Jun 13. pii: 201617467.
    PubMed     Text format     Abstract available


    May 2017

  12. Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
    Proc Natl Acad Sci U S A. 2017 May 22. pii: 201706353.
    PubMed     Text format    


    March 2017
  13. BANERJEE S, Zare RN, Tibshirani RJ, Kunder CA, et al
    Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.
    Proc Natl Acad Sci U S A. 2017 Mar 14. pii: 201700677.
    PubMed     Text format     Abstract available


    November 2016
  14. LORENZO G, Scott MA, Tew K, Hughes TJ, et al
    Tissue-scale, personalized modeling and simulation of prostate cancer growth.
    Proc Natl Acad Sci U S A. 2016 Nov 16. pii: 201615791.
    PubMed     Text format     Abstract available


    October 2016
  15. FERRARA F, Staquicini DI, Driessen WH, D'Angelo S, et al
    Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Oct 24. pii: 201615400.
    PubMed     Text format     Abstract available


    September 2016
  16. STOYANOVA T, Riedinger M, Lin S, Faltermeier CM, et al
    Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Sep 30. pii: 201614529.
    PubMed     Text format     Abstract available


  17. ALHASAN AH, Scott AW, Wu JJ, Feng G, et al
    Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Sep 6. pii: 201611596.
    PubMed     Text format     Abstract available


    June 2016
  18. AHMAD I, Mui E, Galbraith L, Patel R, et al
    Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Jun 29. pii: 201601571.
    PubMed     Text format     Abstract available


  19. RAINA K, Lu J, Qian Y, Altieri M, et al
    PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Jun 6. pii: 201521738.
    PubMed     Text format     Abstract available


    May 2016
  20. KOMURA K, Jeong SH, Hinohara K, Qu F, et al
    Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Proc Natl Acad Sci U S A. 2016 May 16. pii: 201600420.
    PubMed     Text format     Abstract available


    April 2016
  21. PARK JW, Lee JK, Phillips JW, Huang P, et al
    Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
    Proc Natl Acad Sci U S A. 2016;113:4482-7.
    PubMed     Text format     Abstract available


    March 2016
  22. SYKES EA, Dai Q, Sarsons CD, Chen J, et al
    Tailoring nanoparticle designs to target cancer based on tumor pathophysiology.
    Proc Natl Acad Sci U S A. 2016;113:E1142-51.
    PubMed     Text format     Abstract available


    February 2016
  23. HOSOYA H, Dobroff AS, Driessen WH, Cristini V, et al
    Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release.
    Proc Natl Acad Sci U S A. 2016;113:1877-82.
    PubMed     Text format     Abstract available


    January 2016
  24. FENG FY, Kothari V
    Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer.
    Proc Natl Acad Sci U S A. 2016 Jan 8. pii: 201522938.
    PubMed     Text format    


  25. LINCH SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, et al
    Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Proc Natl Acad Sci U S A. 2016 Jan 4. pii: 201510518.
    PubMed     Text format     Abstract available


    November 2015
  26. FALTERMEIER CM, Drake JM, Clark PM, Smith BA, et al
    Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.
    Proc Natl Acad Sci U S A. 2015 Nov 30. pii: 201521674.
    PubMed     Text format     Abstract available


  27. ELLIS L, Loda M
    Advanced neuroendocrine prostate tumors regress to stemness.
    Proc Natl Acad Sci U S A. 2015;112:14406-7.
    PubMed     Text format    


  28. FEHR D, Veeraraghavan H, Wibmer A, Gondo T, et al
    Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images.
    Proc Natl Acad Sci U S A. 2015;112:E6265-E6273.
    PubMed     Text format     Abstract available


  29. COSTA HA, Leitner MG, Sos ML, Mavrantoni A, et al
    Discovery and functional characterization of a neomorphic PTEN mutation.
    Proc Natl Acad Sci U S A. 2015;112:13976-81.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: